Glucocorticosteroids and Postradiation Macular Edema: Rationale for Choice of Therapy and Efficacy of Use
Open Access
- 2 October 2024
- journal article
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 21 (3) , 533-539
Abstract
Purpose. To substantiate and study the effectiveness of intravitreal injection of dexamethasone implant (“Ozurdex”) based on OCT study of morphostructural biomarkers of post-radiation macular edema (PMO) in different terms of its detection.Patients and methods. 28 patients with PMO after Ru-106 ± Rh-106 (BT) brachytherapy for choroidal melanoma (CM). Study group (IG 1) — 18 patients with PMO detected up to 9 months after BT, IG 2 — 10 patients with PMO detected 9 months or more after BT. OCT parameters studied: height of foveolar and parafoveolar zones, presence of neuroepithelium detachment, disorganization of inner layers, hyperreflective foci, pigment epithelium atrophy, as well as the form of edema (diffuse, cystic) and ellipsoid zone disorder. Intravitreal injections of dexamethasone implant (“Ozurdex”) were used as drug therapy of PMO.The results showed that OCT morphostructural changes such as neuroepithelial detachment were significantly more frequent in patients with PMO diagnosed before 9 months, while hyperreflective foci, disorganization of the inner retinal layers, and ellipsoid zone disorder were more frequent in the comparison group. At the same time, there was no statistically significant difference in the macular and parafoveal edema height, frequency of edema form and presence of such a sign as pigment epithelium atrophy in both groups. Evaluation of the efficacy of intravitreal injection of “Ozurdex” implant in both groups showed that after 1–2 months from the beginning of treatment in the group with early detection of PMO complete regression was obtained in all patients, while in the second studied group complete regression occurred only in one third of patients. The regression of PMO was accompanied by improvement of BCVA in the first group from 0.4 to 0.7, in the second group — from 0.3 to 0.6. Out of 28 patients, 3 patients required re-injection of the implant in average 11 months after the first injection.Conclusion. The OCT biomarkers of PMO should be considered in treatment planning and subsequent dynamic follow-up. Early diagnosis of PMO, as well as the use of intravitreal dexamethasone implant (“Ozurdex”) determines high efficiency of treatment and maximum visual rehabilitation of patients.Keywords
This publication has 23 references indexed in Scilit:
- Association of Disorganization of Retinal Inner Layers With Visual Acuity In Eyes With Uveitic Cystoid Macular EdemaAmerican Journal of Ophthalmology, 2017
- Outcomes After Proton Beam Therapy for Large Choroidal Melanomas in 492 PatientsAmerican Journal of Ophthalmology, 2016
- Outcome of Treatment of Uveitic Macular EdemaOphthalmology, 2015
- Diabetic Macular Edema: Pathophysiology and Novel Therapeutic TargetsOphthalmology, 2015
- Subretinal Fluid in Uveitic Macular Edema: Effect on Vision and Response to TherapyAmerican Journal of Ophthalmology, 2013
- Subfoveal Serous Retinal Detachment in Patients With Uveitic Macular EdemaArchives of Ophthalmology (1950), 2011
- The Impact of Intravitreal Bevacizumab Therapy on Choroidal MelanomaAmerican Journal of Ophthalmology, 2011
- Proton beam radiotherapy for uveal melanoma: Results of Curie Institut–Orsay Proton Therapy Center (ICPO)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays)American Journal of Ophthalmology, 2004
- Plaque Radiotherapy for Uveal MelanomaLong-term Visual Outcome in 1106 Consecutive PatientsArchives of Ophthalmology (1950), 2000